Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4727404 | 0.88 | ADORA1 (0.46) | KDM4EPOLBADORA1SLC29A1 | |
| SCHEMBL4727394 | 0.88 | ADORA1 (0.46) | KDM4EPOLBADORA1SLC29A1 | |
| SCHEMBL31629565 | 0.88 | POLB (0.49) | POLBADORA1SLC29A1 | |
| SCHEMBL11683614 | 0.87 | POLB (0.61) | POLBADORA1SLC29A1 | |
| SCHEMBL15143709 | 0.87 | POLB (0.61) | POLBADORA1SLC29A1 | |
| SCHEMBL19519648 | 0.87 | POLB (0.61) | POLBADORA1SLC29A1 | |
| SCHEMBL12362206 | 0.87 | POLB (0.61) | POLBADORA1SLC29A1 | |
| SCHEMBL20534948 | 0.86 | POLB (0.51) | POLBADORA1SLC29A1 | |
| SCHEMBL11049246 | 0.86 | POLB (0.51) | POLBADORA1SLC29A1 | |
| SCHEMBL29776898 | 0.85 | P2RY12 (0.44) | POLBADORA1SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023191365-A1 | IRPEX LACTEUS AM003 STRAIN, CROP DISEASE CONTROL EFFECT CAUSED THEREBY, AND AGRO-INDUSTRIAL APPLICATIONS | 이성기 | 2023-10-05 | — | — | WO | claimed |
| US-20260027048-A1 | GEMFIBROZIL FORMULATION | POLARYX THERAPEUTICS, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4517451-A1 | INFORMATION PROCESSING APPARATUS, INFORMATION PROCESSING METHOD, AND INFORMATION PROCESSING PROGRAM | Yokogawa Electric Corporation (JP) | 2025-03-05 | — | — | EP | disclosed |
| US-20250068437-A1 | INFORMATION PROCESSING APPARATUS, INFORMATION PROCESSING METHOD, AND COMPUTER-READABLE RECORDING MEDIUM | YOKOGAWA ELECTRIC CORPORATION (JP) | 2025-02-27 | — | — | US | disclosed |
| CN-119512622-A | Information processing apparatus, information processing method, and computer-readable recording medium | 横河电机株式会社 | 2025-02-25 | — | — | CN | disclosed |
| US-20240082244-A1 | PHARMACEUTICAL FORMULATION | REDX PHARMA PLC (GB) | 2024-03-14 | — | — | US | disclosed |
| EP-4277606-A1 | PHARMACEUTICAL FORMULATION | Redx Pharma Plc (GB) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023191365-A1 | IRPEX LACTEUS AM003 STRAIN, CROP DISEASE CONTROL EFFECT CAUSED THEREBY, AND AGRO-INDUSTRIAL APPLICATIONS | 이성기 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023191365-A1 | IRPEX LACTEUS AM003 STRAIN, CROP DISEASE CONTROL EFFECT CAUSED THEREBY, AND AGRO-INDUSTRIAL APPLICATIONS | 이성기 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023191365-A1 | IRPEX LACTEUS AM003 STRAIN, CROP DISEASE CONTROL EFFECT CAUSED THEREBY, AND AGRO-INDUSTRIAL APPLICATIONS | 이성기 | 2023-10-05 | — | — | WO | disclosed |
| CN-114181311-B | Fully human anti-DLL 3 scFv and application thereof in CART cell therapy | 华东师范大学 | 2023-06-20 | — | — | CN | disclosed |
| CN-115239477-A | Interest calculation method and device | 中国银行股份有限公司 | 2022-10-25 | — | — | CN | disclosed |
| US-20220260578-A1 | Fluorescent Methods and Materials for Directed Biomarker Signal Amplification | SIRIGEN, INC. | 2022-08-18 | — | — | US | disclosed |
| WO-2022153062-A1 | PHARMACEUTICAL FORMULATION | REDX PHARMA PLC (GB) | 2022-07-21 | — | — | WO | disclosed |
| CN-114181311-A | Fully human anti-DLL 3scFv and application thereof in CART cell treatment | 华东师范大学 | 2022-03-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027048-A1 | GEMFIBROZIL FORMULATION | LIPC, FFAR4, FFAR2 | KDM4E 1066/4885POLB 3832/4885ADORA1 1235/4885 |
| US-20240082244-A1 | PHARMACEUTICAL FORMULATION | TREH, SQLE, CYP3A5 | KDM4E 2776/4885POLB 3987/4885ADORA1 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.